rare disease

Immedica to Acquire Biopharma Company Marinus

Stockholm, Sweden-headquartered global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals, a US commercial-stage pharmaceutical company developing therapies for seizure disorders, for enterprise value of approximately $151 million.

News

Pfizer Doubles Dublin Biologicals Capacity

Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.

Topics • Strategy

After Pharma’s Patent Cliff

Top-Feature

Dow Chemical Company

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Interview

Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

SchüllerConsulting

Immedica Pharma AB

rare disease

Immedica to Acquire Biopharma Company Marinus

Pfizer Doubles Dublin Biologicals Capacity

After Pharma’s Patent Cliff

Top-Feature

Anchored in Sustainability

20 Years of CHEManager International

Driving Sustainability Through Collaboration

Brenntag Downsizes Management Board, Retains Both Divisions

Advanced Recycling Conference 2025: New Paths to the Circular Economy

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

API Manufacturing

Leading the way. Driving results.

Leading Transformation

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Interview

Driving Sustainability Through Collaboration

Newsletter & e-edition